Uterine leiomyosarcoma (LMS) is the most common sarcoma arising from the uterus and comprises approximately 2% of uterine cancers. Patients diagnosed with LMS have a 5-year overall survival ranging from 25-75% . The primary management of LMS is hysterectomy. Adjuvant pelvic radiotherapy has been shown to improve local control and survival of patients with leiomyosarcoma.
Leiomyosarcoma medical therapy
Sexcord/ stromal ovarian tumors medical therapy
Endometrial cancer medical therapy
Leiomyosarcoma surgery
Leiomyosarcoma secondary prevention
Endometrial hyperplasia medical therapy
Endometriosis medical therapy
Ovarian germ cell tumor medical therapy